# A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

> **NCT02483247** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 165 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** BBI503
- **DRUG:** Capecitabine
- **DRUG:** Doxorubicin
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT02483247
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483247, "A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02483247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*